MSP-1014 selected based on head-to-head comparison to psilocybin and its active metabolite psilocin MSP-1014 showed greater safety and efficacy in in vitro and in vivo preclinical models Cost effective for cGMP manufacturing and IND-enabling studies TORONTO, June 03, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and…


Previous articleCOMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers
Next articleOp-ed: UK Public Support Psilocybin Research & Rescheduling Despite Government Stance